Advanced Science (Feb 2022)

Remote and Selective Control of Astrocytes by Magnetomechanical Stimulation

  • Yichao Yu,
  • Christopher Payne,
  • Nephtali Marina,
  • Alla Korsak,
  • Paul Southern,
  • Ana García‐Prieto,
  • Isabel N. Christie,
  • Rebecca R. Baker,
  • Elizabeth M. C. Fisher,
  • Jack A. Wells,
  • Tammy L. Kalber,
  • Quentin A. Pankhurst,
  • Alexander V. Gourine,
  • Mark F. Lythgoe

DOI
https://doi.org/10.1002/advs.202104194
Journal volume & issue
Vol. 9, no. 6
pp. n/a – n/a

Abstract

Read online

Abstract Astrocytes play crucial and diverse roles in brain health and disease. The ability to selectively control astrocytes provides a valuable tool for understanding their function and has the therapeutic potential to correct dysfunction. Existing technologies such as optogenetics and chemogenetics require the introduction of foreign proteins, which adds a layer of complication and hinders their clinical translation. A novel technique, magnetomechanical stimulation (MMS), that enables remote and selective control of astrocytes without genetic modification is described here. MMS exploits the mechanosensitivity of astrocytes and triggers mechanogated Ca2+ and adenosine triphosphate (ATP) signaling by applying a magnetic field to antibody‐functionalized magnetic particles that are targeted to astrocytes. Using purpose‐built magnetic devices, the mechanosensory threshold of astrocytes is determined, a sub‐micrometer particle for effective MMS is identified, the in vivo fate of the particles is established, and cardiovascular responses are induced in rats after particles are delivered to specific brainstem astrocytes. By eliminating the need for device implantation and genetic modification, MMS is a method for controlling astroglial activity with an improved prospect for clinical application than existing technologies.

Keywords